The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Hopefully will see buys coming in today. Very held stock and shifts very quickly. Can see institutions buying in today. Excellent RNs yesterday. Gla
Mms withholding buys and printing them down later. Mms accumulating to fill orders.
Sold Value £479.32k
Bought Value £920.46k
Https://www.alliancepharmaceuticals.com/investors/shareholder-centre/significant-shareholders/
Wow. Peeps selling out on a loss
Couple of 60000 plus buys printed from few hours ago.
(Alliance News) - Redx Pharma PLC on Wednesday said it has struck a deal to sell Kirsten rat sarcoma virus inhibitor program to Dublin-based Jazz Pharmaceuticals PLC.
Redx Pharma shares soared 44% to 28.70 pence each in London on Wednesday morning.
The Macclesfield, England-based clinical-stage biotechnology company said it will receive USD10 million upfront, with a potential for up to USD870 million in development, regulatory and sales milestone payments in addition to royalties on future net sales.
Jazz Pharmaceuticals and Redx will collaborate to advance candidates through IND-enabling studies; Jazz Pharmaceuticals will be responsible for all clinical development, regulatory, manufacturing and commercialisation activities.
Lots of 50000 buys getting printed from earlier in the morning over 30p.
Moves very quick.
Mms short of shares
-------
Redx Pharma PLC, up 35% at 27.00 pence, 12-month range 19.00p-60.00p. The clinical-stage biotechnology company signs an agreement to sell Kirsten rat sarcoma virus inhibitor program to Jazz Pharmaceuticals PLC. Redx says it will receive USD10 million upfront, with a potential for up to USD870 million in development, regulatory and sales milestone payments in addition to royalties on future net sales. Jazz and Redx will collaborate to advance candidates through IND-enabling studies; Jazz will be responsible for all clinical development, regulatory, manufacturing and commercialization activities.
Yearly high 57 last February
Proposed Placing and Subscription to raise gross proceeds of a minimum £5.8 million (approximately US$7.4 million) (before expenses) at the Issue Price.
The net proceeds of the Fundraise will be used for drilling an exploration well (Itumbula West-A) on the Itumbula prospect, in addition to general working capital purposes. No more placing required